Patent US4460575A successfully refreshed from Google Patents.
US4460575A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Vaccinal complex containing a specific antigen and vaccine containing it
Assignee: Pierre Fabre SA
•
Filing: 1981-02-20
•
Granted: 1984-07-17
•
Expires: 2001-02-20
Abstract
Abstract The present invention relates to a vaccinal complex containing a specific antigen. This is a vaccinal complex characterized in that it is composed of bacterial ribosomal RNA or fragments of bacterial ribosomal RNA on which are coupled from 1 to 5% by weight of a specific antigen of bacterial serotype. This complex may be used as a vaccine.
Inventors
- 👤 Lucien D. d'Hinterland
- 👤 Gerard Normier
- 👤 Anne-Marie Pinel
- 👤 Jacques Durand
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 11:13
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/39; A61K2039/555; A61K2039/55511; A61K2039/55583; Y; Y10; Y10S; Y10S424/00; Y10S424/831; Y10S530/00; Y10S530/807
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
33 words
A vaccinal complex comprising RNA selected from bacterial ribosomal RNA and fragments of bacterial ribosomal RNA, on which are coupled from 1 to 5% by weight of a specific antigen of bacterial serotype.
Claim 2
Dependent Claim
33 words
A vaccinal complex comprising RNA selected from bacterial ribosomal RNA and fragments of bacterial ribosomal RNA, on which are coupled from 1 to 5% by weight of a specific antigen of bacterial serotype.
Claim 3
Dependent Claim
19 words
A complex according to claim 1, wherein the RNA and the specific antigen originate from the same bacterial strains.
Claim 4
Dependent Claim
18 words
A complex according to claim 1, wherein the RNA and the specific antigen originate from different bacterial strains.
Claim 5
Dependent Claim
33 words
A complex according to claim 1, wherein the specific antigen is selected from the following: Capsular polysaccharides, Membrane lipopolysaccharides of gram-negative bacteria, specific membrane proteins, and teichoic and lipopteichoic acids of gram-negative bacteria.
Claim 6
Dependent Claim
32 words
A complex according to claim 4, wherein the specific antigen is selected from capsular polysaccharides of at least one of the following species: Klebsiella pneumoniae, Streptococcus pneumoniae, Hemophilus influenzae, and Escherichia coli.
Claim 7
Dependent Claim
34 words
A complex according to claim 4, wherein the specific antigen is selected from membrane lipopolysaccharides of at least one of the following species: Klebseilla pneumoniae, Serratia marcescens, Escherichia coli, Neisseria meningitidis, and Salmonella typhimurium.
Claim 8
Dependent Claim
33 words
A complex according to claim 4, wherein the specific antigen is selected from specific membrane proteins of at least one of the following species: Escherichia coli, Serratia marcescens, Salmonella typhimurium, and Streptococcus pyogenes.
Claim 9
Dependent Claim
29 words
A complex according to claim 4, wherein the specific antigen is selected from teichoic and lipoteichoic acids of at least one of the following genera: Streptococci, Staphylococci, and Lactobacillae.
Claim 10
Dependent Claim
38 words
A complex according to claim 1, wherein the ribosomal RNA is extracted from the ribosomes of at least one of the following: Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Klebsiella pneumoniae, Serratia marcescens, Escherichia coli, Salmonella typhimurium, Corynebacterium, Mycobacterium.
Claim 11
Dependent Claim
25 words
A complex according to claim 1, wherein the fragments of bacterial ribosomal RNA have a molecular weight of between 3×10 4 and 2×10 5 daltons.
Claim 12
Dependent Claim
22 words
A complex according to claim 10, wherein the fragments of bacterial ribosomal RNA have a molecular weight of between 30,000 and 50,000.
Claim 13
Dependent Claim
13 words
A complex according to claim 1, wherein coupling is produced by covalent bonds.
Claim 14
Dependent Claim
25 words
A vaccine against pathogenic bacteria comprising a pharmaceutically acceptable support and an effective amount of the vaccinal complex of claim 1 to inoculate a patient.
Claim 15
Dependent Claim
16 words
A method for inoculating a patent comprising administering to said patient the vaccine of claim 13.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-17 | 1988-01-16 | 1988-07-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-17 | 1992-01-16 | 1992-07-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-17 | 1996-01-16 | 1996-07-17 | $7700.00 | Window Closed / Lapsed |